Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma.
Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reassessment. Moderate to severe nausea occurred in 24% of patients. In the dose and schedule used in this study, tamoxifen is ineffective in patients with advanced malignant melanoma and prior chemotherapy exposure.
D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011960:Receptors, Estrogen / Q000032:analysis; D012878:Skin Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects
D011960:Receptors, Estrogen; D013629:Tamoxifen